The key
players in Transfection Equipment Market are continuously striving to gain larger shares and
expand their existing product portfolios by agreements, collaborations, and
partnerships. The overall market was dominated by Thermo Fisher Scientific Inc.
(U.S.), Promega Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland),
and QIAGEN N.V. (Netherlands). Other players include Polyplus-transfection SA
(France), Bio-Rad Laboratories Inc. (U.S.), Lonza Group (Switzerland),
Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte, Inc.
(U.S.).
Thermo Fisher Scientific Inc. to Dominate the Global Transfection Equipment Market
Thermo
Fisher Scientific Inc. (U.S.) is leading player in the transfection reagents
and equipment market with a market share of ~61.5% in 2015. The company
primarily focuses on growth strategies such as acquisitions to add innovative
technologies and products to its portfolio, which in turn helps the company to
strengthen its presence in the respective markets.
Thermo Fisher acquired
Affymetrix, Inc. (U.S.) in 2016, Advanced Scientifics, Inc. (U.S.) in 2015, and
Life Technologies Corporation (U.S.) in 2014. This helped the company to expand
its customer base and significantly boost its market share. The company’s major
share in the transfection reagents and equipment market can be attributed to
its broad product portfolio, years of experience, and extensive distribution
channel.
The R&D expenditure of the company for
2015 was USD 690 million, which enabled it to expand its product portfolio in
the transfection reagents and equipment market, and to further enhance its customer
base. In November 2014, Thermo Fisher Scientific introduced its Lipofectamine
MessengerMAX, a high-efficiency transfection reagent for mRNA delivery in
neurons and primary cell types.
You Can Also Talk to Our Research Experts for More Detailed Information
It is five times more efficient as compared to
DNA reagents and helps researchers in easy transfection of biologically
relevant cell models without electroporation or viruses. The company‘s
distribution network comprises a broad sales force and global network of
resellers and distributors. Thermo Fisher has approximately 17,500 sales and
service personnel, including over 3,000 trained technical specialists who address
the diversified demands of technical end users.
Promega Corporation (U.S.) is another dominant player in the transfection
reagents and equipment market. The company accounted for approximately ~17.4%
of the market revenue generation. The firm offers more than 3000 products for
life science research, particularly in genomics, protein analysis and
expression, cellular analysis, drug discovery, and genetic identity. It offers
various transfection reagents under its reporter assays and transfection
category of products. Promega has branches in 16 countries with more than 50
global distributors.
The company possesses a strong intellectual property
portfolio, which helps it to maintain its position in the life science market.
Promega owns more than hundred patents in the field of nucleic acid
purification, human identification, bioluminescence, coupled in vitro
transcription and translation, and cell biology. The company focuses on the strategy
of new product development and expansion to strengthen its position in the
market.
Players operating in the transfection reagents and equipment market
adopted strategies such as agreements, collaborations, and partnerships to
strengthen their global presence. The
key players that have adopted these strategies include MaxCyte,
Inc. (U.S.), Polyplus-transfection SA (France), QIAGEN N.V. (Netherlands), Lonza
Group Ltd. (Switzerland), F. Hoffmann-La Roche ltd (Switzerland), and Thermo
Fisher Scientific Inc. (U.S.)
No comments:
Post a Comment